| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment |
| Creator | Alcaraz et al. |
| Author | Lindsay B. Alcaraz |
| Author | Aude Mallavialle |
| Author | Timothée David |
| Author | Danielle Derocq |
| Author | Frédéric Delolme |
| Author | Cindy Dieryckx |
| Author | Caroline Mollevi |
| Author | Florence Boissière-Michot |
| Author | Pitter F. Huesgen |
| Author | Christopher M. Overall |
| Author | Sophie Tartare-Deckert |
| Author | William Jacot |
| Author | Thierry Chardès |
| Author | Séverine Guiu |
| Author | Pascal Roger |
| Author | Thomas Reinheckel |
| Author | Catherine Moali |
| Author | Emmanuelle Liaudet-Coopman |
| Abstract | Rationale: Alternative therapeutic strategies based on tumor-specific molecular targets are urgently needed for triple-negative breast cancer (TNBC). The protease cathepsin D (cath-D) is a marker of poor prognosis in TNBC and a tumor-specific extracellular target for antibody-based therapy. The identification of cath-D substrates is crucial for the mechanistic understanding of its role in the TNBC microenvironment and future therapeutic developments. Methods: The cath-D substrate repertoire was investigated by N-Terminal Amine Isotopic Labeling of Substrates (TAILS)-based degradome analysis in a co-culture assay of TNBC cells and breast fibroblasts. Substrates were validated by amino-terminal oriented mass spectrometry of substrates (ATOMS). Cath-D and SPARC expression in TNBC was examined using an online transcriptomic survival analysis, tissue micro-arrays, TNBC cell lines, patient-derived xenografts (PDX), human TNBC samples, and mammary tumors from MMTV-PyMT Ctsd-/- knock-out mice. The biological role of SPARC and its fragments in TNBC were studied using immunohistochemistry and immunofluorescence analysis, gene expression knockdown, co-culture assays, western blot analysis, RT-quantitative PCR, adhesion assays, Transwell motility, trans-endothelial migration and invasion assays. Results: TAILS analysis showed that the matricellular protein SPARC is a substrate of extracellular cath-D. In vitro, cath-D induced limited proteolysis of SPARC C-terminal extracellular Ca2+ binding domain at acidic pH, leading to the production of SPARC fragments (34-, 27-, 16-, 9-, and 6-kDa). Similarly, cath-D secreted by TNBC cells cleaved fibroblast- and cancer cell-derived SPARC at the tumor pericellular acidic pH. SPARC cleavage also occurred in TNBC tumors. Among these fragments, only the 9-kDa SPARC fragment inhibited TNBC cell adhesion and spreading on fibronectin, and stimulated their migration, endothelial transmigration, and invasion. Conclusions: Our study establishes a novel crosstalk between proteases and matricellular proteins in the tumor microenvironment through limited SPARC proteolysis, revealing a novel targetable 9-kDa bioactive SPARC fragment for new TNBC treatments. Our study will pave the way for the development of strategies for targeting bioactive fragments from matricellular proteins in TNBC. |
| Publication | Theranostics |
| Volume | 11 |
| Issue | 13 |
| Pages | 6173-6192 |
| Date | 2021 |
| Journal Abbr | Theranostics |
| Language | eng |
| DOI | 10.7150/thno.58254 |
| ISSN | 1838-7640 |
| Library Catalog | PubMed |
| Extra | PMID: 33995652 PMCID: PMC8120228 |
| Tags | Amino Acid Sequence, Animals, Binding Sites, bioactive fragment, Cathepsin D, Cell Adhesion, ECM, Female, Fibroblasts, Gene Expression Regulation, Neoplastic, Humans, Hydrogen-Ion Concentration, Mammary Neoplasms, Experimental, marque, matricellular protein, Mice, Mice, Knockout, Mice, Transgenic, Molecular Weight, Neoplasm Invasiveness, Neoplasm Proteins, original, Osteonectin, Peptide Fragments, Protein Domains, Proteolysis, Substrate Specificity, TNBC, Transendothelial and Transepithelial Migration, Triple Negative Breast Neoplasms, Tumor Microenvironment |
| Date Added | 2022/07/29 - 15:51:43 |
| Date Modified | 2022/08/01 - 11:54:49 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
